Published Paper Details:

Esomeprazole magnesium trihydrate (ESO), bis(5-methoxy- 2-[(S)- [(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] sulfinyl]-1-H-benzimidazole-1-yl)magnesium trihydrate Figure 1, A compound called esomeprazole magnesium trihydrate prevents the secretion of stomach acid. When treating conditions related to gastric oesophageal reflux, ESO is an affordable option. The first single optical isomer proton pump inhibitor, omeprazole, has an S-isomer called ESO. It has a good pharmacokinetic profile compared to omeprazole and generally offers better acid control than contemporary racemic proton pump inhibitors. Esomeprazole and omeprazole show significant similarities with respect to of pharmacokinetics, mechanism of action, and clinical efficacy. In the US, omeprazole is prescribed to treat peptic ulcer disease, gastroesophageal reflux disease, and the prevention of stress ulcers1. Gastroesophageal reflux disease (GERD), but is especially suitable for people with GERD who have recurring, chronic symptoms that can be disruptive and last a long time2. Literature survey reveals esomeprazole magnesium trihydrate that is determined by RP-HPLC, LC-MS/MS, UPLC, UVHPLC, UPLC--MS/MS and UV Spectrophotometry